Answers are grounded in this paper and cite their sources.
Following a single oral dose of 1.25 g sulfapyridine (SP), the pharmacokinetic properties of this moiety of sulfasalazine were evaluated in healthy volunteers. While there was no difference in the absorption characteristics, plasma protein binding (49.6 ± 3.3%), and apparent distribution volume (0.9 ± 0.4 liters/kg) between fast (n = 4) and slow (n = 5) acetylators, elimination half-life (5.5 ± 1.2 vs 15.3 ± 2.2 hr: p < 0.0001), and total plasma clearance (135.3 ± 50.3 vs. 36.9 ± 12.2 ml/min: p = 0.002) demonstrated marked differences between these two phenotypes. In 57 patients with Crohn's disease and 47 patients with ulcerative colitis (53% slow and 47% fast acetylators), plasma levels were monitored routinely. Plasma levels were in the suggested “therapeutic” range of 20–50 μg total SP/ml in 60% of patients, which was associated in 53% of the cases with a good therapeutic response. Of the 40% of patients exhibiting plasma levels below 20 μg/ml, only 27% demonstrated a good response. This difference is probably due to the better absorption seen in well-controlled patients. Multiple plasma level determinations over 0.5–2 years were performed in 9 patients with Morbus Crohn and 2 patients with ulcerative colitis. No significant correlation between dose and plasma levels of SP or its acetylated metabolite was found. In addition, neither SP nor total SP plasma levels demonstrated a relationship with the therapeutic response to sulfasalazine. Thus the existence of a so-called “therapeutic” range appears to be highly questionable. Side effects (nausea, headache, vomiting, allergic reactions) were seen with an overall frequency of 17%. In some cases they were associated with high plasma levels.
No takes yet. Share an insight, caveat, or question.
Fischer et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: